2Duraker N, Hot S, Polar Y, et al. CEA. CA 19-9. and CAI25 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice [J]. J Surg Oncol, 2007, 95 (2) : 142-147.
3Koom WS, Seong J, Kim YB, et al. CA19-9 as a predict or for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy [J]. In t J Radiat Oncol Biol Phys, 2009, 73 (4): 1148-1154.
4Tsavaris N, Kosmas C, Papadoniou N, et al. CEA and CA19-9 serum tumor markers as prognostic factors in patients with locally advanced (urtreseetable) or metastatic pancreatic adenoearcinoma: aretros pective analysis [J]. J Chemother, 2009, 21 (6) : 673- 680.
5Duffy M J, Sturgeon C, Lamerz R, et al. Tumor marker-s in pancreatic cancer: a European Group on Tumor Markers (EGTM) statusreport [J] . Ann Oncol. 2010. 21 (3): 441-447.
6Carpelan Holmstroti M,Louhimo J,Stenman UH,et al.CEA,CA199,and CA72-4 improve the diagnostic accuracy in gastrointestinal cancers[J].Anticancer Res,2002;22(4):2311-6.
7Chantapet P,Raintawan P,Lebnak P,et al.Utility of serumcy tokeratin 19 fragment(CYFRA21-1)and carcinoembryonic antigen(CEA)as tumormarkers for non-small cell lung cancer[J].Med Assoc Thai,2000;83(4):383-91.
